| Investor Relations |
Five-Year Summary
Mitsubishi Pharma Corporation and Consolidated Subsidiaries
Millions of yen Thousands of
U.S. dollars
2006 2005 2004 2003 2002 2006
Years ended March 31:
Net sales 
¥ 236,207 ¥ 234,244 ¥ 235,431 ¥ 280,780 ¥ 228,983 $ 2,018,863
Cost of sales 
81,444 81,712 83,812 120,736 105,272 696,102
Selling, general and
  administrative expenses 
118,528 121,483 122,892 130,596 103,746 1,013,060
Operating income 
36,235 31,049 28,727 29,448 19,965 309,701
Net income 
20,699 13,172 10,818 8,255 8,988 176,915
 
At March 31:
Current assets 
¥ 205,342 ¥ 181,710 ¥ 179,363 ¥ 207,640 ¥ 218,296 $ 1,755,060
Property, plant
  and equipment, net 
77,309 84,546 87,060 105,375 104,787 660,761
Investments and other assets 
24,401 24,372 29,777 27,760 29,481 208,555
Total assets 
307,052 290,628 296,200 340,775 352,564 2,624,376
Current liabilities 
57,573 63,911 65,619 117,309 128,101 492,077
Long-term liabilities 
7,585 9,856 21,570 21,988 24,034 64,829
Minority interests 
10,353 10,880 11,470 12,496 8,044 88,487
Shareholders’ equity 
231,541 205,981 197,541 188,982 192,385 1,978,983
Yen U.S. dollars
Amounts per share:
Net income 
¥ 45.39 ¥ 29.02 ¥ 23.81 ¥ 18.05 ¥ 24.54 $ 0.39
Cash dividends applicable
  to the year 
20.44 10.00 10.00 10.00 11.00 0.17
Thousands of shares
Common stock issued 
458,435 458,435 458,435 458,435 458,435   
  
AR TOP |

Profile
Financial Highlights
Message from the President
Business results
Establishment of Joint Holding Company
Launch of Joint Holding Company, Mitsubishi Chemical Holdings Corporation, from October 2005
Strengthening Pharmaceutical Business through Joint Holding Company Structure
Meeting Tomorrow’s Challenge in Personalized Medicine
Mid-term Corporate Action Plan
Mid-term Corporate Action Plan — On Target
Maximization of Sales and Marketing Strengths
Optimization of Production and Technology Divisions
Target of Total Cost Reduction Achieved
Increasing the Certainty of Research and Development Results and Establishment of Global Marketing Basis
R&D
Strengthening Research and Development
Product Pipeline
Corporate Social Responsibility
Improving Corporate Governance System
Reinforced Implementation of Compliance
Global Environmental Conservation: a Task for Every Individual
Harmony with Society
Financial Section
Five-Year Summary
Management’s Discussion and Analysis
Balance Sheets
Income Statements
Shareholders’ Equity
Cash Flows
Notes
Auditors’ Report
Corporate Data

Mitsubishi Chemical Holdings Corporation Investor Center
Copyright© Mitsubishi Pharma Corporation. All Rights Reserved.